Related Party Transactions (Tables)

3 Months Ended

Mar. 31, 2026

Schedule of effective date and PIK dividend or equity fee payable


				PIK Dividend as
				a % of fully
				diluted
				outstanding		Class of Stock
Partner Company/Subsidiary		Effective Date ¹		capitalization		Issued
Avenue		February 17, 2015		2.5	%	Common Stock
Cellvation		October 31, 2016		2.5	%	Common Stock
Checkpoint		March 17, 2015		—	%²	Common Stock
Cyprium		March 13, 2017		2.5	%	Common Stock
Helocyte		March 20, 2015		2.5	%	Common Stock
LemmaTx		February 11, 2026 ³		2.5	%	Common Stock
Mustang		March 13, 2015		2.5	%	Common Stock
Oncogenuity		April 22, 2020 ³		2.5	%	Common Stock
Urica		November 7, 2017 ³		2.5	%	Common Stock

Note 1:

Represents the effective date of the Founders Agreement of each subsidiary/partner company. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement or has since been amended to January 1 of each calendar year.

Note 2:

Instead of a PIK dividend, Checkpoint paid the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization. Due to the deconsolidation of Checkpoint in May 2025 related to the Sun Pharma transaction (see Note 3), Checkpoint no longer has this obligation to the Company.

Note 3:

Represents the Trigger Date, the date that the Fortress partner company/subsidiary first acquires, whether by license or otherwise, ownership rights in a product.

Schedule of effective date and annual consulting fee payable by the subsidiary to the Company



Partner Company/Subsidiary		Effective Date		Annual MSA Fee (Income)/Expense
Avenue		February 17, 2015		$	500
Cellvation		October 31, 2016			500
Checkpoint¹		March 17, 2015			—
Cyprium		March 13, 2017			500
Helocyte		March 20, 2015			500
LemmaTx²		February 11, 2026			442
Mustang		March 13, 2015			500
Oncogenuity		February 10, 2017			500
Urica		November 7, 2017			500
Fortress					(3,942)
Consolidated (Income)/Expense				$	—

Note 1:Checkpoint was acquired by Sun Pharma in May 2025 (see Note 3).

Note 2:Lemma’s MSA fee for the year ended December 31, 2026 is pro-rated for its 2026 effective date of its MSA.